For chronic low back pain, cognitive therapy, mindfulness-based stress reduction, and behavior therapy all appear to work by progressively weakening the link between pain-related thoughts or pain spikes and later outcomes, rather than by directly changing those mechanisms. In a study of 521 people, associations between treatment mechanism variables and outcomes were strong early in treatment but became nonsignificant by the final third. This decoupling effect was similar across the three active treatments but did not occur in treatment as usual. The findings suggest that by midtreatment, participants may learn that maladaptive thoughts or pain increases need not worsen their subsequent experience.
Barriers to a clinical trial of ketamine for acute sickle cell disease pain include lack of standardized protocols (50.6% of clinicians) and provider attitudes about ketamine (32.5%). Patients cited trust in providers and potential health benefits as facilitators but worried about safety, confidentiality, and time commitment. Clinicians showed varied comfort with ketamine, differing between sickle cell and emergency medicine specialists. Successful implementation requires multidisciplinary approaches, transparent communication, strong clinical frameworks, and patient-centered trial designs.